Marshall Wace North America L.P. lowered its stake in Proteostasis Therapeutics, Inc. (NASDAQ:PTI) by 8.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 684,124 shares of the company’s stock after selling 59,172 shares during the period. Marshall Wace North America L.P. owned 2.73% of Proteostasis Therapeutics worth $3,421,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of PTI. Russell Investments Group Ltd. bought a new position in Proteostasis Therapeutics during the first quarter valued at about $100,000. Dynamic Technology Lab Private Ltd bought a new position in Proteostasis Therapeutics during the first quarter valued at about $112,000. LMR Partners LLP bought a new position in Proteostasis Therapeutics during the second quarter valued at about $127,000. Trexquant Investment LP raised its position in Proteostasis Therapeutics by 1.0% in the first quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock valued at $155,000 after buying an additional 190 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in Proteostasis Therapeutics by 21.4% in the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after buying an additional 2,223 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) opened at 2.24 on Friday. Proteostasis Therapeutics, Inc. has a 52-week low of $1.71 and a 52-week high of $16.67. The company’s market capitalization is $56.23 million. The company’s 50-day moving average price is $2.63 and its 200 day moving average price is $6.28.

TRADEMARK VIOLATION NOTICE: “Marshall Wace North America L.P. Sells 59,172 Shares of Proteostasis Therapeutics, Inc. (PTI)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/02/marshall-wace-north-america-l-p-sells-59172-shares-of-proteostasis-therapeutics-inc-pti.html.

Several equities analysts recently issued reports on PTI shares. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a research report on Friday, June 30th. Zacks Investment Research upgraded Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Leerink Swann restated an “outperform” rating and set a $9.00 price target (down from $17.00) on shares of Proteostasis Therapeutics in a research report on Wednesday, August 16th.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Stock Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related stocks with our FREE daily email newsletter.